Fulgent Genetics, Inc. (FLGT) Surpasses Q2 Earnings and Revenue Estimates

Core Viewpoint - Fulgent Genetics, Inc. reported quarterly earnings of $0.07 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.23 per share, marking an earnings surprise of +130.43% [1] Financial Performance - The company posted revenues of $81.8 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 7.80% and showing an increase from $71.03 million year-over-year [2] - Over the last four quarters, Fulgent Genetics has surpassed consensus EPS estimates four times and topped consensus revenue estimates four times as well [2] Stock Performance - Fulgent Genetics shares have declined approximately 7% since the beginning of the year, contrasting with the S&P 500's gain of 7.8% [3] Future Outlook - The company's earnings outlook will be crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.22 on revenues of $78.25 million, and -$0.62 on revenues of $309.87 million for the current fiscal year [7] Industry Context - The Medical Info Systems industry, to which Fulgent Genetics belongs, is currently ranked in the top 23% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]